Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development

In 2017, the World Health Organization (WHO) named A. baumannii as one of the three antibiotic-resistant bacterial species on its list of global priority pathogens in dire need of novel and effective treatment. With only polymyxin and tigecycline antibiotics left as last-resort treatments, the need for novel alternative approaches to the control of this bacterium becomes imperative. Vaccines against numerous bacteria have had impressive records in reducing the burden of the respective diseases and addressing antimicrobial resistance; as in the case of Haemophilus influenzae type b . A similar approach could be appropriate for A. baumannii. Toward this end, several potentially protective antigens against A. baumannii were identified and evaluated as vaccine antigen candidates. A licensed vaccine for the bacteria, however, is still not in sight. Here we explore and discuss challenges in vaccine development against A. baumannii and the promising approaches for improving the vaccine development process.

Automated summary

The World Health Organization has identified A. baumannii as a top priority pathogen in need of new and effective treatment due to antibiotic resistance. With limited antibiotic options available, alternative approaches such as vaccines have shown promise in reducing disease burden and addressing antimicrobial resistance, suggesting that a similar approach may work for A. baumannii. While several potentially protective antigens have been identified for the bacteria, a licensed vaccine is still not yet available. Challenges in vaccine development against A. baumannii are being explored, along with promising approaches for improving the vaccine development process.